Molecular Characterization of Human Leukemia 60 (HL-60) Cells as a Model of Acute Myelogenous Leukemia Post Cryopreservation

  • Noha A. S. Al-Otaibi
  • Juliana S. Cassoli
  • Nigel K. H. Slater
  • Hassan RahmouneEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1916)


The use of human leukemic (HL)-60 cells is important for studies of acute myeloid leukemia (AML) and as a model system for investigating how specific types of blood cells are formed during the process of hematopoiesis. Here, we present a protocol for growth of HL-60 cells along with molecular and functional profiles associated with their cryostorage. We also elucidate the effects of these procedures on cell viability and functions. This method can be used to provide biomarkers as readouts for testing the efficacy and/or toxicity of novel compounds in AML research as well as in a number of other experimental manipulations.

Key words

Cell model Cancer Leukemia HL-60 cells Malignancy Proteomics Cryopreservation Biomarkers 


  1. 1.
    Koeffler HP, Golde DW (1980) Human myeloid leukemia cell lines: a review. Blood 56(3):344–350PubMedGoogle Scholar
  2. 2.
    Si C, Gallo RC, Gallagher RE (1997) Continuous growth anddifferentiation of human myeloid Ieukaemic cells in suspension culture. Nature 270:347–349Google Scholar
  3. 3.
    Renshaw AA1, Hughes JH, Wang E, Haja J, Wilbur D, Henry MR et al (2006) Leukemia/lymphoma in cerebrospinal fluid: distinguishing between cases that performed well and poorly in the College of American Pathologists Interlaboratory Comparison Program in non-gynecologic cytology. Arch Pathol Lab Med 130(12):1762–1765PubMedGoogle Scholar
  4. 4.
    Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S et al (1979) Characterization of the continuous, differentiating myeloid cell line(HL-60) from a patient with acute promyelocytic leukemia. Blood 54:713–733PubMedGoogle Scholar
  5. 5.
    Strassberger V, Gutbrodt KL, Krall N, Roesli C, Takizawa H, Manz MG et al (2014) A comprehensive surface proteome analysis of myeloid leukemia cell lines for therapeutic antibody development. J Proteome 99:138–151CrossRefGoogle Scholar
  6. 6.
    Wang WJ, Tang W, Qiu ZY (2009) Comparative proteomics analysis on differentiation of human promyelocytic leukemia HL-60 cells into granulocyte and monocyte lineages. Ai Zheng 8(2):117–121Google Scholar
  7. 7.
    Nakazaki E, Tsolmon S, Han J, Isoda H (2013) Proteomic study of granulocytic differentiation induced by apigenin 7-glucoside in human promyelocytic leukemia HL-60 cells. Eur J Nutr 52(1):25–35CrossRefPubMedGoogle Scholar
  8. 8.
    Hagemann UB, Wickstroem K, Wang E, Shea AO, Sponheim K, Karlsson J et al (2016) In vitro and in vivo efficacy of a novel CD33-targeted Thorium-227 conjugate for the treatment of acute myeloid leukemia. Mol Cancer Ther 15(10):2422–2431CrossRefPubMedGoogle Scholar
  9. 9.
    Geromanos SJ, Hughes C, Ciavarini S, Vissers JPC, Langridge JI (2012) Using ion purity scores for enhancing quantitative accuracy and precision in complex proteomics samples. Anal Bioanal Chem 404(4):1127–1139CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Noha A. S. Al-Otaibi
    • 1
    • 2
  • Juliana S. Cassoli
    • 3
  • Nigel K. H. Slater
    • 1
  • Hassan Rahmoune
    • 1
    Email author
  1. 1.Department of Chemical Engineering and BiotechnologyUniversity of CambridgeCambridgeUK
  2. 2.King Abdulaziz City for Science and Technology Kingdom of Saudi ArabiaPO, RiyadhSaudi Arabia
  3. 3.Faculty of MedicineFederal University of Tocantins (UFT)PalmasBrazil

Personalised recommendations